Bank of America Spends Over $250 Million a Year on GLP-1s
Bank of America is spending more than $250 million per year on GLP-1 weight-loss drugs for its workforce of more than 210,000 employees. CEO Brian Moynihan calls it a worthwhile investment tied to short- and long-term health benefits such as lower heart-disease risk, while noting the firm seeks cheaper options as pills become available.